Avoiding Common Pitfalls in the IND and CTA Submission Process

[Fill out the form below to register]

Abstract: When planning an Investigational New Drug (IND) or Clinical Trial Authorization (CTA) submission, navigating FDA, EMA, and other regulations can be challenging and creating scientifically-sound strategies are essential. As submissions expand to multiple countries during later phase trials, greater challenges can arise if not prepared with knowledge of the requirements, proper time management, and defined roles for the team towards approval. 

Join us as experts in project management, medical writing, and regulatory operations discuss best practices for a successful submission process from start to finish. 

Attendees will learn:

  • Efficiencies for multi-country submissions 
  • Essential steps in pre-submission planning 
  • Timeline management and potential pitfalls 
  • How to define roles and responsibilities to avoid delays or confusion 
  • Structure and content of the submissions at various stages of development 
  • Navigating the country–specific regulatory requirements 
  • Post-submission maintenance and responsibilities 

Presenters:

Jessica Reed, PhD, Senior Manager, Project and Account Management  

Nicole Northrop, PhD, Manager, Regulatory and Medical Writing 

Allison Ward, MSA, MSEd, Senior Manager, Regulatory Operations 

Avoiding Common Pitfalls in the IND and CTA Submission Process

Register for the webinar

Suggested For You

perspectives

November 6th, 2024

How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure

perspectives

October 29th, 2024

Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies

perspectives

October 22nd, 2024

Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development

perspectives

October 15th, 2024

Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer